A Phase 4 interventional study of FPNS and FPNS Placebo in Rhinitis, Allergic, Perennial and Seasonal, sponsored by GlaxoSmithKline. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-20.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Cetirizine · Rhinitis, Allergic, Seasonal.
Among the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 6 in phase 4, and was the 9th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Cetirizine: first FDA approval 1995 (ZYRTEC HIVES). What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 682 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 117 across the 10 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 31 finished, 10 (32%) have results posted.
Among the 31 studies in Rhinitis, Allergic, Seasonal by GlaxoSmithKline, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2013, is one of 5 in phase 4, and was the 29th registered.
GlaxoSmithKline’s Rhinitis, Allergic, Seasonal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Rhinitis, Allergic, Seasonal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs. cetirizine on allergic nasal and ocular symptoms and quality of life in adult subjects with SAR. It is hypothesized that FPNS provides greater nasal symptom relief than cetirizine. The primary measure used to test this hypothesis is the change from baseline over two weeks in reflective total nasal symptom score (rTNSS) compared between FPNS and cetirizine. Approximately 648 subjects will be randomized into a 1:1:1:1 ratio of treatment allocation across approximately twenty-five to thirty-five sites in the US during the 2013 fall allergy season. All subjects will be outpatients. The total duration of study will be approximately 21 days including 7 days of screening period, and 14 days of treatment period.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
This study's enrollment of 682 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Visit 2, the subject must meet the following criteria
Exclusion Criteria
Historical or current evidence of a uncontrolled disease of any body system (e.g., tuberculosis, psychological disorders, eczema, uncontrolled asthma). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or which would confound the interpretation of the study results if the disease/condition exacerbated during the study.
A severe physical obstruction of the nose (e.g., deviated septum or nasal polyp) or nasal septal perforation that could affect the deposition of intranasal study drug.
Nasal (e.g., nasal septum), ocular, or throat injury, or surgery to these areas in the last 3 months.
Rhinitis medicamentosa. Bacterial or viral infection (e.g., common cold) of the eyes or upper respiratory tract within two weeks of Visit 1 or during the screening period.
Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator.
Current or history of glaucoma and/or cataracts or ocular herpes simplex. Physical impairment that would affect subject's ability to safely and fully participate in the study.
Clinical evidence of a Candida infection of the nose. History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse (including drug and alcohol) or other conditions that will limit the validity of or that would confound the interpretation of the study results.
History of adrenal insufficiency.
Leukotriene modifiers (\<=3 days from Visit 1). Oral antihistamines (\<=2 days from Visit 1). Allergy medications, other than study supplied medications, are not allowed during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
Drug: FPNS
Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
Drug: FPNS Placebo
Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
Drug: Cetirizine
Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
Drug: Cetirizine Placebo
Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
Mean Change From Baseline (CFB) in the Individual AM Reflective Total Nasal Symptom Scores (rTNSS) Over the Entire Treatment Period
The rTNSS score is the sum of the four individual symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing. Each symptom is scored on a scale ranging from 0 to 3; the rTNSS ranges from 0 (none) to 12 (severe). Each individual symptom was evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The reflective assessment of the TNSS scores the four nasal symptoms over the previous 24 hours. The participants themselves scored nasal symptoms in an e-diary. Baseline is defined as the arithmetic average of the rTNSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks)
Mean Change From Baseline in the Individual AM Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion, Nasal Itching, and Sneezing Over the Entire Treatment Period
Each individual symptom was evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe).The reflective assessment scores the four nasal symptoms over the previous 24 hours. The participants themselves scored nasal symptoms in an e-diary. Baseline is defined as the arithmetic average of the individual AM reflective nasal symptom scores recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks)
Mean Change From Baseline in the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) Overall Score at Visit 3/Early Withdrawal.
The NRQLQ is a 16-item, validated, self-administered, disease (allergic rhinitis)-specific quality of life instrument that measures the functional problems most troublesome to participants with nocturnal allergy symptoms over a one-week interval. Each question is scored on a 7-point scale from 0 (not troubled) to 6 (extremely troubled). Items are grouped into four domains: sleep problems (4 items), sleep time problems (5 items), symptoms on waking in the morning (4 items), and practical problems (3 items). An overall score was calculated from the individual item scores. All items are weighted equally. A mean score is calculated across all items within each domain. The overall score is the mean across all items and ranges from 0 (not troubled) to 6 (extremely troubled). Higher scores reflect a lower quality of life. Change from Baseline was calculated as the 2-week average minus the Baseline value.
Time frame: Baseline and Visit 3 (Study Day 14 +/- 2 days)/Early Withdrawal
Mean Change From Baseline in the AM Pre-dose Instantaneous Total Nasal Symptom Score (iTNSS) Over the Entire Treatment Period
The iTNSS score is the sum of the four individual symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing. Each symptom is scored on a scale ranging from 0 to 3; the iTNSS ranges from 0 (none) to 12 (severe). The symptoms were evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The instantaneous assessment of the TNSS scores the four nasal symptoms at the time of the assessment, or at that "instant." The participants themselves scored nasal symptoms in an e-diary once each morning prior to administering study drug. Baseline is defined as the arithmetic average of the iTNSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days.
Time frame: Baseline through the entire treatment period (2 weeks)
Mean Change From Baseline in the AM Pre-dose Reflective Total Ocular Symptom Score (rTOSS) Over the Entire Treatment Period
The rTOSS is an eye assessment that comprises the sum of the three symptom scores for tearing/watering, itching/burning, and eye redness. Each symptom is scored on a scale of 0 to 3: 0, none; 1, mild; 2, moderate; 3, severe. The rTOSS ranges from 0 (none) to 9 (severe). The reflective assessment scores the participants' ocular symptoms over the preceding 24 hours. The participants themselves scored ocular symptoms in an e-diary. Baseline arithmetic is defined as the average of the rTNSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks)
Mean Change From Baseline in the AM Pre-dose Instantaneous Total Ocular Symptom Score (iTOSS) Over the Entire Treatment Period
The iTOSS is an eye assessment that comprises the sum of the three symptom scores for tearing/watering, itching/burning, and eye redness. Each symptom is scored on a scale of 0 to 3: 0, none; 1, mild; 2, moderate; 3, severe. The iTOSS ranges from 0 (none) to 9 (severe). The instantaneous assessment scores the participants' ocular symptoms at the time of the assessment, or at that "instant." The participants themselves scored ocular symptoms in an e-diary once each morning prior to administering study drug. Baseline is defined as the arithmetic average of the iTOSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
Time frame: Baseline through the entire treatment period (2 weeks)
Mean Change From Baseline in the Combined Nasal and Ocular Reflective Total Symptom Score (rTSS = rTNSS+rTOSS) Over the Entire Treatment Period
The rTSS is the sum of the rTNSS and the rTOSS. The rTNSS score is the sum of the four individual symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing. Each symptom is scored on a scale ranging from 0 to 3; the rTNSS ranges from 0 (none) to 12 (severe). Each individual symptom was evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The rTOSS assessment is comprised of the sum of the three symptom scores for tearing/watering, itching/burning, and eye redness. Each symptom is scored on a scale of 0 to 3: 0, none; 1, mild; 2, moderate; or 3, severe. The rTOSS ranges from 0 (none) to 9 (severe). The reflective assessment scores participants' symptoms over the previous 24 hours. The participants themselves scored nasal and ocular symptoms in an e-diary. Baseline is defined as the arithmetic average of the rTSS recorded on the morning of randomization and on each of the six preceding days.
Time frame: Baseline through the entire treatment period (2 weeks)
In anticipation of a 5% to 8% dropout rate, this study planned enrolment of 156 participants per treatment group in order to target 144 participants per treatment group, who would provide a full 2 weeks' worth of data.
| Milestone | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Started | 170 | 170 | 171 | 171 |
| Completed | 169 | 169 | 168 | 167 |
| Not completed | 1 | 1 | 3 | 4 |
| Withdrew: Adverse event | 1 | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
The rTNSS score is the sum of the four individual symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing. Each symptom is scored on a scale ranging from 0 to 3; the rTNSS ranges from 0 (none) to 12 (severe). Each individual symptom was evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The reflective assessment of the TNSS scores the four nasal symptoms over the previous 24 hours. The participants themselves scored nasal symptoms in an e-diary. Baseline is defined as the arithmetic average of the rTNSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Mean Change From Baseline (CFB) in the Individual AM Reflective Total Nasal Symptom Scores (rTNSS) Over the Entire Treatment Period | -2.2 ± 0.19 | -1.9 ± 0.18 | -1.5 ± 0.18 | -0.9 ± 0.16 |
Each individual symptom was evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe).The reflective assessment scores the four nasal symptoms over the previous 24 hours. The participants themselves scored nasal symptoms in an e-diary. Baseline is defined as the arithmetic average of the individual AM reflective nasal symptom scores recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Nasal congestion | -0.5 ± 0.05 | -0.4 ± 0.04 | -0.3 ± 0.05 | -0.2 ± 0.04 |
| Nasal itching | -0.6 ± 0.05 | -0.5 ± 0.05 | -0.4 ± 0.05 | -0.2 ± 0.04 |
| Runny nose | -0.5 ± 0.05 | -0.4 ± 0.05 | -0.4 ± 0.05 | -0.3 ± 0.05 |
| Sneezing | -0.6 ± 0.05 | -0.6 ± 0.05 | -0.4 ± 0.05 | -0.2 ± 0.05 |
The NRQLQ is a 16-item, validated, self-administered, disease (allergic rhinitis)-specific quality of life instrument that measures the functional problems most troublesome to participants with nocturnal allergy symptoms over a one-week interval. Each question is scored on a 7-point scale from 0 (not troubled) to 6 (extremely troubled). Items are grouped into four domains: sleep problems (4 items), sleep time problems (5 items), symptoms on waking in the morning (4 items), and practical problems (3 items). An overall score was calculated from the individual item scores. All items are weighted equally. A mean score is calculated across all items within each domain. The overall score is the mean across all items and ranges from 0 (not troubled) to 6 (extremely troubled). Higher scores reflect a lower quality of life. Change from Baseline was calculated as the 2-week average minus the Baseline value.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) Overall Score at Visit 3/Early Withdrawal. | -1.0 ± 0.10 | -0.6 ± 0.09 | -0.8 ± 0.10 | -0.5 ± 0.08 |
The iTNSS score is the sum of the four individual symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing. Each symptom is scored on a scale ranging from 0 to 3; the iTNSS ranges from 0 (none) to 12 (severe). The symptoms were evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The instantaneous assessment of the TNSS scores the four nasal symptoms at the time of the assessment, or at that "instant." The participants themselves scored nasal symptoms in an e-diary once each morning prior to administering study drug. Baseline is defined as the arithmetic average of the iTNSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in the AM Pre-dose Instantaneous Total Nasal Symptom Score (iTNSS) Over the Entire Treatment Period | -1.9 ± 0.18 | -1.3 ± 0.17 | -1.2 ± 0.18 | -0.6 ± 0.15 |
The rTOSS is an eye assessment that comprises the sum of the three symptom scores for tearing/watering, itching/burning, and eye redness. Each symptom is scored on a scale of 0 to 3: 0, none; 1, mild; 2, moderate; 3, severe. The rTOSS ranges from 0 (none) to 9 (severe). The reflective assessment scores the participants' ocular symptoms over the preceding 24 hours. The participants themselves scored ocular symptoms in an e-diary. Baseline arithmetic is defined as the average of the rTNSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in the AM Pre-dose Reflective Total Ocular Symptom Score (rTOSS) Over the Entire Treatment Period | -1.6 ± 0.16 | -1.4 ± 0.16 | -1.2 ± 0.16 | -0.8 ± 0.14 |
The iTOSS is an eye assessment that comprises the sum of the three symptom scores for tearing/watering, itching/burning, and eye redness. Each symptom is scored on a scale of 0 to 3: 0, none; 1, mild; 2, moderate; 3, severe. The iTOSS ranges from 0 (none) to 9 (severe). The instantaneous assessment scores the participants' ocular symptoms at the time of the assessment, or at that "instant." The participants themselves scored ocular symptoms in an e-diary once each morning prior to administering study drug. Baseline is defined as the arithmetic average of the iTOSS recorded on the morning of randomization and on each of the six preceding days. A participant may have had as few as 4 days' worth of data contributing to the Baseline average. The 2-week symptom score was defined as the average of the values recorded on the day after randomization and the following 13 days. Change from Baseline was thus calculated as the 2-week average minus the Baseline value.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in the AM Pre-dose Instantaneous Total Ocular Symptom Score (iTOSS) Over the Entire Treatment Period | -1.3 ± 0.15 | -1.1 ± 0.14 | -1.1 ± 0.16 | -0.5 ± 0.13 |
The rTSS is the sum of the rTNSS and the rTOSS. The rTNSS score is the sum of the four individual symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing. Each symptom is scored on a scale ranging from 0 to 3; the rTNSS ranges from 0 (none) to 12 (severe). Each individual symptom was evaluated using a scale of 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The rTOSS assessment is comprised of the sum of the three symptom scores for tearing/watering, itching/burning, and eye redness. Each symptom is scored on a scale of 0 to 3: 0, none; 1, mild; 2, moderate; or 3, severe. The rTOSS ranges from 0 (none) to 9 (severe). The reflective assessment scores participants' symptoms over the previous 24 hours. The participants themselves scored nasal and ocular symptoms in an e-diary. Baseline is defined as the arithmetic average of the rTSS recorded on the morning of randomization and on each of the six preceding days.
| Scores on a scale | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in the Combined Nasal and Ocular Reflective Total Symptom Score (rTSS = rTNSS+rTOSS) Over the Entire Treatment Period | -3.9 ± 0.34 | -3.4 ± 0.34 | -2.7 ± 0.34 | -1.7 ± 0.30 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until the End-of-Study visit (up to Day 14).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FPNS 200 μg | — | 0/170 (0%) | 10/170 (5.9%) |
| Cetirizine 10 mg | — | 0/170 (0%) | 13/170 (7.6%) |
| FPNS Matching Placebo | — | 0/171 (0%) | 10/171 (5.8%) |
| Cetirizine Matching Placebo | — | 0/171 (0%) | 10/171 (5.8%) |
| Event | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 2/170 | 3/170 | 2/171 | 3/171 |
| Upper respiratory tract infectionInfections and infestations | 2/170 | 0/170 | 0/171 | 0/171 |
| Viral upper respiratory tract infectionInfections and infestations | 2/170 | 0/170 | 0/171 | 0/171 |
| Back painMusculoskeletal and connective tissue disorders | 0/170 | 2/170 | 0/171 | 0/171 |
| Fungal infectionInfections and infestations | 1/170 | 0/170 | 0/171 | 1/171 |
| Gastroenteritis viralInfections and infestations | 1/170 | 0/170 | 1/171 | 0/171 |
| NasopharyngitisInfections and infestations | 0/170 | 1/170 | 0/171 | 0/171 |
| Sinus headacheNervous system disorders | 0/170 | 1/170 | 0/171 | 0/171 |
| SomnolenceNervous system disorders | 0/170 | 1/170 | 0/171 | 0/171 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/170 | 1/170 | 1/171 | 0/171 |
| Age, Continuous(Years) | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo | Total |
|---|---|---|---|---|---|
| Mean | 40.1 ± 10.66 | 39.2 ± 11.41 | 41.3 ± 11.29 | 40.4 ± 11.84 | 40.3 ± 11.31 |
| Sex: Female, Male(Participants) | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo | Total |
|---|---|---|---|---|---|
| Female | 96 | 113 | 110 | 109 | 428 |
| Male | 74 | 57 | 61 | 62 | 254 |
| Race/Ethnicity, Customized(Participants) | FPNS 200 μg | Cetirizine 10 mg | FPNS Matching Placebo | Cetirizine Matching Placebo | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 34 | 20 | 31 | 35 | 120 |
| American Indian or Alaska Native | 1 | 0 | 1 | 1 | 3 |
| Asian - Central/South Asian Heritage | 2 | 2 | 5 | 3 | 12 |
| Asian-East Asian Heritage | 1 | 0 | 1 | 0 | 2 |
| Asian - South East Asian Heritage | 2 | 0 | 1 | 2 | 5 |
| White - Arabic/North African Heritage | 1 | 0 | 1 | 1 | 3 |
| White - White/Caucasian/European Heritage | 129 | 142 | 128 | 127 | 526 |
| Mixed Race | 0 | 6 | 3 | 1 | 10 |
| Not Captured by Study Site | 0 | 0 | 0 | 1 | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Aug 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
Rhinitis, Allergic, Seasonal →